Business Context and Reporting Period
Company: Mesoblast Limited (Mesoblast)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Three months ended September 30, 2017
Business Overview: Mesoblast is a global leader in developing innovative cellular medicines based on mesenchymal lineage adult stem cells (MLCs). The company focuses on late-stage product candidates for cardiovascular, orthopedic, immunologic, and oncologic conditions. The company is dual-listed on the Australian Securities Exchange (ASX) and the NASDAQ Global Select Market.
Key Financial Metrics
| Metric (in thousands USD) | Q3 2017 | Q3 2016 |
|---|---|---|
| Revenue | $1,174 | $395 |
| Net Loss | $(7,022) | $(19,798) |
| Loss Per Share (Basic & Diluted) | $(1.60) | $(5.24) |
| Operating Cash Flow | $(20,356) | $(20,827) |
| Cash and Cash Equivalents (End of Period) | $62,941 | $60,355 |
| Total Assets | $671,898 | N/A |
| Total Liabilities | $112,308 | N/A |
Note: Q3 2016 comparative balance sheet data is not provided in the text; only income statement and cash flow comparisons are available.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 197% to $1.2 million, driven by a $0.5 million milestone payment from licensee JCR Pharmaceuticals for TEMCELL sales in Japan and increased royalty income ($0.6 million vs. $0.2 million).
- Net Loss Reduction: Net loss decreased significantly by 65% to $7.0 million. This improvement was primarily due to a $9.5 million non-cash gain from the remeasurement of contingent consideration related to the Osiris acquisition, compared to a $1.0 million loss in the prior year.
- Expense Management:
- R&D Expenses: Increased 10% to $15.4 million due to higher third-party costs for Tier 1 clinical programs (CHF, CLBP, aGVHD), partially offset by reduced product support costs from operational streamlining.
- Manufacturing Expenses: Decreased 73% to $0.9 million due to fewer production runs required for clinical supply.
- Admin Expenses: Decreased 8% to $5.0 million due to reduced corporate overheads and legal fees.
- Capital Raise: The company completed a fully underwritten entitlement offer in September 2017, raising approximately A$50.7 million (approx. $38.4 million net cash inflow from financing activities).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress:
- Rheumatoid Arthritis (RA): Phase 2 results presented at the ACR Annual Meeting showed dose-related improvements in clinical symptoms and safety for biologic-refractory RA patients.
- Heart Failure: Enrollment completed for a Phase 2b trial (MPC-150-IM) for end-stage heart failure, funded by the NIH and CIHR.
- Osteoarthritis: Published results showed MPC-75-IA reduced cartilage loss and improved pain/function after traumatic knee injury.
- Capital Requirements: Management anticipates continued losses and increasing expenses as the company advances clinical programs. Future funding will be sought through equity offerings, debt, or strategic partnerships. A discretionary equity facility of up to A$120 million remains available.
- Going Concern: The filing includes a material uncertainty regarding the company's ability to continue as a going concern. Viability depends on securing non-dilutive partnerships for Tier 1 products or raising further capital.
Risks and Contingencies
- Regulatory Risk: No industrially manufactured stem cell products have been approved in the U.S. Approval pathways are uncertain, and clinical trial results are not predictive of future success.
- Manufacturing Risk: Reliance on a single contract manufacturer (Lonza) for clinical and potential commercial supply creates supply chain vulnerability.
- Financial Risk: Significant accumulated deficit of $351.9 million. Continued cash burn requires successful capital raising or partnerships to avoid operational delays.
- Intellectual Property: Risks related to patent protection, enforcement, and potential infringement claims.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $62.9 million cash balance against the $20.3 million quarterly operating cash burn rate and upcoming Phase 3 trial costs.
- Partnership Status: Confirm progress on securing non-dilutive partnerships for the four Tier 1 product candidates, which is critical for the "going concern" assessment.
- Contingent Consideration: Review the assumptions behind the $9.5 million gain on remeasurement of contingent consideration (Osiris acquisition) to understand the volatility of future earnings.
- Clinical Milestones: Monitor upcoming data readouts for the Phase 2b Heart Failure trial and Phase 3 programs to assess regulatory pathway viability.
- Revenue Sustainability: Assess the sustainability of royalty and milestone revenue from JCR Pharmaceuticals in Japan, which currently constitutes the majority of revenue.